• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Aptar Pharma banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Lupin launches authorized generic of Brovana inhalation solution in the US

Lupin has announced the US launch of an authorized generic version of Sunovion's Brovana arformoterol tartrate inhalation solution for the treatment of COPD. The FDA tentatively approved the company's ANDA for the inhalation solution in April 2020. The FDA approved Brovana for the treatment of COPD in 2006, requiring a post-marketing safety study. In 2013, … [Read more...] about Lupin launches authorized generic of Brovana inhalation solution in the US

Evoke gets new US patent for Gimoti nasal spray

Evoke Pharma said that the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,020,361 ("Nasal Formulations of Metoclopramide”) covering methods of use for Gimoti metoclopramide nasal spray for the treatment of gastroparesis until at least 2029. The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020. Evoke … [Read more...] about Evoke gets new US patent for Gimoti nasal spray

Noveome signs agreement for commercial use of SipNose intranasal device for delivery of ST266

Noveome Biotherapeutics has signed a commercial license agreement for the use of SipNose’s intranasal Cribriform Targeted Device (CT6) for delivery of its ST266 secretome for the treatment of ophthalmological and CNS conditions the companies said. Noveome has been working with SipNose since 2015 and used the device in a Phase 1 trial of ST266 for optic nerve disease … [Read more...] about Noveome signs agreement for commercial use of SipNose intranasal device for delivery of ST266

AIM Immunotech extends deal with Smoore related to development of inhaled Ampligen

AIM ImmunoTech said that it has extended a 2020 agreement with Shenzhen Smoore Technology related to development of an inhaled version of its Ampligen rintatolimod for the treatment of COVID-19. The agreement with Smoore is for the use of a Smoore-designed "personal inhalation device designed to administer Ampligen, given temperature parameters of dsRNA." According to … [Read more...] about AIM Immunotech extends deal with Smoore related to development of inhaled Ampligen

Inhalon Biopharma gets US Army contract for development of inhaled antibody for the treatment of COVID-19

According to North Carolina-based startup Inhalon Biopharma, the US Army Medical Research & Development Command (USAMRDC) has awarded the company a contract worth $7 million for a Phase 1/2a study of its IN-006 inhaled neutralizing monoclonal antibody for the treatment of COVID-19 in an outpatient setting. The company expects topline results to be available in … [Read more...] about Inhalon Biopharma gets US Army contract for development of inhaled antibody for the treatment of COVID-19

Vectura to be acquired by the Carlyle Group

A newly formed company called Murano Bidco, which is controlled by the Carlyle Group, has agreed to pay approximately £958 million to acquire inhalation CDMO Vectura, the companies have announced. According to the announcement, Bidco was formed specifically for the purpose of acquiring Vectura. Vectura Chairman Bruno Angelici commented, "Vectura has made strong … [Read more...] about Vectura to be acquired by the Carlyle Group

GSK sells its stake in Innoviva

Innoviva is buying back GlaxoSmithKline's entire stake in the company, a total of 32 million shares (~ 32% of company). Innoviva (formerly Theravance, Inc.), was spun off from Theravance in 2013 to manage the royalties from dry powder inhalers that Theravance developed in partnership with GSK, including Relvar/Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta. GSK will … [Read more...] about GSK sells its stake in Innoviva

Iconovo announces deal with Respiratorius for development of DPI

Iconovo will develop a dry powder formulation and a DPI for Phase 1 studies for Swedish respiratory drug company Respiratorius AB on a fee for service basis in a deal worth up to SEK 3 million, the company said. The project, which involves development of Respiratorius's RES030-085 for the treatment of COPD and severe asthma, would lead to a license agreement if … [Read more...] about Iconovo announces deal with Respiratorius for development of DPI

Ji Xing Pharmaceuticals gets Chinese rights to etripamil for PVST

Milestone Pharmaceuticals has announced a new agreement with Ji Xing Pharmaceuticals giving Ji Xing Chinese development and commercialization rights to Milestone's etripamil nasal spray in patients with cardiovascular conditions, including paroxysmal supraventricular tachycardia (PSVT). Ji Xing will pay $15 million up front and up to $107.5 million in milestone and … [Read more...] about Ji Xing Pharmaceuticals gets Chinese rights to etripamil for PVST

Akroswiss gets funding for development of midazolam nasal spray

Swiss start-up Akroswiss has announced that it raised "several million Swiss Franc" for development of the company's midazolam nasal spray for the prevention of claustrophobia and for the rescue treatment of epileptic seizures. Investors include Linsi, Bernhard Schuknecht, and Walter P. Hölzle, who is also the company's Head of Business Development. According to the … [Read more...] about Akroswiss gets funding for development of midazolam nasal spray

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews